A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy
NCT06085664
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
To learn about the safety and effects of a drug called REGN5678 when it is given to patients with high-risk prostate cancer.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Prostate Cancer
- Radical Prostatectomy
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- M.D. Anderson Cancer Center
- Last updated on ClinicalTrials.gov
- August 25, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Texas · 1
- M D Anderson Cancer Center · Houston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.